- Arcus Biosciences (RCUS, Financial) has granted new employment inducement options and restricted stock units to three employees.
- The options cover a total of 39,750 shares with an exercise price of $8.11 per share, matching the closing price on April 23, 2025.
- The equity awards are part of Arcus's 2020 Inducement Plan.
Arcus Biosciences, Inc. (RCUS), a leading clinical-stage biopharmaceutical company, announced that its Compensation Committee has granted employment inducement options to three new employees. These options allow the purchase of a total of 39,750 shares of the company's common stock at an exercise price of $8.11 each, which was the closing price as of April 23, 2025.
In addition to stock options, these new hires have been granted restricted stock units, representing a total of 19,950 shares of common stock. These equity awards are issued under Arcus's 2020 Inducement Plan, leveraging the "inducement exception" per NYSE Listed Company Manual Rule 303A.08.
Arcus Biosciences, founded in 2015 and headquartered in Hayward, California, aims to develop innovative therapies for cancer treatment. Their efforts include pioneering combination therapies with a focus on well-characterized biological targets such as TIGIT, PD-1, and HIF-2a, among others. For more details on their clinical and preclinical programs, visit Arcus Biosciences' official website.
